Neurocrine Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Neurocrine Biosciences (NBIX).

Price Target Range — 7 Quarters

Analyst Consensus — 23 Analysts

21Buy

2Hold

Consensus RatingBuy# Analysts23Avg. Consensus PT$200Upside to Avg. PT+41.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	Guggenheim	Delma Caiati	Assumes	Buy	$207
Sep 29, 2026	UBS	Ashwani Verma	PT Cut	Buy	$231→$214
Sep 11, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$182→$183
Sep 8, 2026	RBC Capital	Brian Abrahams	Maintained	Outperform	$198
Sep 3, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$249→$253
Aug 13, 2026	Morgan Stanley	Jeffrey Hung	PT Cut	Equal-Weight	$196→$182
Aug 3, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$200→$210
Aug 3, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$200→$213
Aug 3, 2026	Wedbush	Laura Chico	PT Raise	Outperform	$185→$194
Jul 31, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$246→$249
Jul 31, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$195→$198
Jul 31, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$193→$196
Jul 31, 2026	TD Cowen	Phil Nadeau	PT Raise	Buy	$200→$220
Jul 31, 2026	Piper Sandler	David Amsellem	PT Raise	Overweight	$207→$210
Jul 31, 2026	Cantor Fitzgerald	Josh Schimmer	PT Raise	Overweight	$210→$215
Jul 31, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$200→$222
Jul 31, 2026	Stifel	Paul Matteis	PT Raise	Buy	$188→$215
Jul 31, 2026	Needham	Ami Fadia	PT Raise	Buy	$200→$204
Jul 21, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$175→$200
Jul 17, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$175→$200

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207

Guggenheim analyst Delma Caiati assumes Neurocrine Biosciences (NASDAQ:NBIX) with a Buy rating and announces Price Target of $207.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214

UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $231 to $214.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $182 to $183.

Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target

RBC Capital analyst Brian Abrahams reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and maintains $198 price target.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253

Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $249 to $253.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and lowers the price target from $196 to $182.

Benzinga Newsdesk

Neurocrine Biosciences Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Neurocrine Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207

PRO
UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183

PRO
RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target

PRO
Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182

People Also Watch

People Also Watch

Neurocrine Biosciences Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Neurocrine Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207

PROUBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214

PROMorgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183

PRORBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target

PROCitigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253

PROMorgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182

People Also Watch

People Also Watch

PRO
Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207

PRO
UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183

PRO
RBC Capital Reiterates Outperform on Neurocrine Biosciences, Maintains $198 Price Target

PRO
Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253

PRO
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182